What Is OMass Therapeutics

OMass Therapeutics is a private biotechnology company, focused on structural mass spectrometry to discover novel medicines.

The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulation of complex formation, with both effects, binding and function, being measured by a change in mass. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors.

The

Science

We are developing novel medicines using our suite of proprietary technologies based on high-resolution mass spectrometry of intact protein assemblies.

Read More

Overview

About Us

We are a biotechnology company using structural mass spectrometry to discover novel medicines.

Read More

Latest News

OMass Therapeutics’ Founder & Scientific Advisor, Professor Carol Robinson, receives a Royal Society Medal
July 23, 2019

Oxford, 23 July 2019 – OMass Therapeutics (“OMass”), a drug discovery company using structural mass spectrometry to discover novel medicines, today…

Read More
OMass Therapeutics’ Founder & Scientific Advisor Honoured – Professor Carol Robinson wins 2019 Novozymes Prize and Stein & Moore Award –
July 16, 2019

Oxford, 16 July 2019 – OMass Therapeutics (“OMass”), a drug discovery company using structural mass spectrometry to discover novel medicines, today…

Read More
OMass Therapeutics appoints Jonathan Montagu as Non-Executive Director
June 12, 2019

Oxford, 12 June 2019 – OMass Therapeutics (“OMass”), a drug discovery company using structural mass spectrometry to discover novel medicines, today…

Read More
OMass Therapeutics appoints Rosamond Deegan as Chief Executive Officer
May 8, 2019

Oxford, 8 May 2019 – OMass Therapeutics (“OMass”), a drug discovery company using structural mass spectrometry to discover novel medicines, today…

Read More